A review traces the evolution from pramlintide to long-acting amylin analogues, highlighting second-generation non-aggregating peptides advancing through clinical development.
Second-generation amylin drugsNon-aggregating, long-acting analogues advancing through clinical development
What the researchers found
Second-generation non-aggregating, long-acting amylin analogues are advancing in clinical development, offering improved dosing convenience over pramlintide.
Why it matters
Amylin signaling is a key therapeutic target for next-generation obesity and diabetes drugs, complementary to GLP-1-based approaches.
How the study worked
Narrative review of amylin biology, receptor structure, peptide design principles, and clinical development of second-generation amylin analogues.
What this study cannot tell us
Review of emerging therapies — most second-generation agents are still in clinical trials; long-term safety data pending.
How to read the evidence
Narrative review — synthesizes peptide science and clinical development data.
When this study was published
Published 2026 in Peptides.
The bigger picture
Amylin analogues could be combined with GLP-1 RAs for enhanced weight loss (as in cagrilintide/semaglutide combinations), potentially surpassing current monotherapy results.
Questions still open
- Will amylin-GLP-1 RA combinations become the new standard for severe obesity?
- What advantage do amylin analogues offer over GLP-1 RAs alone?
Common questions
What is amylin?
How do amylin drugs differ from GLP-1 drugs?
Read the original research
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Peptides, 196, 171480
Citation
Bailey, Clifford J; Flatt, Peter R; Conlon, J Michael. (2026). Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.. Peptides, 196, 171480. https://doi.org/10.1016/j.peptides.2026.171480